A surgeon who used one of Medtronic‘s (NYSE:MDT) controversial InFuse bone-growth protein spinal implants in an “off-label” lumbar procedure has been acquitted by a California state jury, after Medtronic had already been dropped from the case as a defendant, according to the Courtroom View Network.
The surgeon, Dr. William Dobkin, was found not negligent in his use of the Infuse device in an 11-1 jury decision, according to the report, based on the fact that he obtained proper consent before using the implant during two lumbar surgeries.
The plaintiff, nurse Christina Avalos, and her defense team claimed that Avalos would not have allowed the device to be used had they known it was not approved by the FDA for lumbar surgeries, according to CVN.
While the legal team for the plaintiff claimed the use of the Infuse protein, which has been shown in the past to cause excessive bone growth, was out of the ordinary, testimony from a Harvard-trained UCSF professor of orthopedic surgery supported that Dobkin’s use of the infuse device was medically acceptable, even though it wasn’t specifically cleared by the FDA.
The defense team also argued that continued pain experienced by Avalos was the result of pre-existing medical conditions that the surgery failed to cure, CVN reports.
Medtronic was originally named as a defendant in the case, but were dropped prior to the trial, according to the report.
Though Medtronic was not a defendant, CVN reported that the case was the first time a jury determined whether a physician’s use of the controversial infuse device was medically negligent.
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.